Persantine: Variation in Response Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00763009 |
Recruitment Status :
Terminated
(Limited numbers of patients qualified for trial)
First Posted : September 30, 2008
Results First Posted : May 24, 2017
Last Update Posted : April 13, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Drug: dipyridamole | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Persantine: Variation in Response Trial |
Actual Study Start Date : | September 2002 |
Actual Primary Completion Date : | July 2009 |
Actual Study Completion Date : | July 2009 |

Arm | Intervention/treatment |
---|---|
All subjects receive dipyridamole
Compare to baseline
|
Drug: dipyridamole
0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
Other Name: Persantine |
- To Determine if There is a Subgroup of Patients That Have an Abnormal Adenosine Transporter Expression, or Abnormal Adenosine Transporter Protein Function. [ Time Frame: 6-12 months ]To determine if there is a subgroup of patients that have an abnormal adenosine transporter expression, or abnormal adenosine transporter protein function. All were responsive Study terminated due to difficulty enrolling
- To Determine the Clinical Significance of Variations in Adenosine Transfer Function on Coronary Flow. [ Time Frame: 6-12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients > 21 years old
- Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex
Exclusion Criteria:
- Theophylline or oral Persantine use in 24hrs
- Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
- Active asthma or bronchospasm
- Patients with severe hepatic insufficiency
- Patients experiencing an acute transmural infarction at the time of the index visit
- Conditions that are known to affect resistive vessel function or myocardial flow

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763009
United States, Connecticut | |
UCONN Health Center | |
Farmington, Connecticut, United States, 06030 |
Principal Investigator: | Michael A Azrin, MD | University of Connecticut | |
Study Chair: | Bruce T Liang, MD | University of Connecticut |
Responsible Party: | UConn Health |
ClinicalTrials.gov Identifier: | NCT00763009 |
Other Study ID Numbers: |
02-202-1 A-13147.1 |
First Posted: | September 30, 2008 Key Record Dates |
Results First Posted: | May 24, 2017 |
Last Update Posted: | April 13, 2018 |
Last Verified: | March 2018 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Coronary Artery Disease Coronary Disease Myocardial Ischemia Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
Vascular Diseases Dipyridamole Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Vasodilator Agents |